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Childhood	is	a	critical	time	for	respiratory	health	with	environmental	and	
infectious	exposures	being	linked	to	future	respiratory	disease	and	
susceptibility1,2.		Respiratory	microbiome	research	has	introduced	a	new	context	
for	these	exposures	due	to	the	presence	of	a	pre‐existing	microbial	community	in	
both	the	upper	and	lower	respiratory	tract	in	healthy	children3‐5.	Variation	in	
community	composition	has	been	observed	in	chronic	lung	diseases6,7	and	
particular	microorganisms	or	combinations	of	organisms	in	infants	have	been	
associated	with	future	disease	development.	Thus	deviation	from	a	healthy	
microbiota	in	early	life	appears	to	play	an	important	role	in	disease	development	
with	changes	evident	by	one	week	of	age8.		The	dynamics	of	the	infant	airway	
microbiota	and	its	relationship	to	disease	development	has	therefore	been	the	
focus	of	increasing	attention.		
	
Acute	respiratory	infections	are	common	in	children	under	five	years	of	age9	and	
indications	suggest	that	susceptibility	might	be,	at	least	partly,	determined	by	
the	microbiota5,8.	Toivonen	and	colleagues	have	conducted	the	largest	study	of	
the	respiratory	microbiome	in	infants	to	date,	obtaining	a	nasal	swab	at	2	
months	of	age	from	839	infants	and	parent	recorded	data	on	respiratory	
infections	until	24	months	of	age	to	look	at	incidence	of	acute	respiratory	
infections	(ARI).		
	
The	study	was		conducted,	described	and	controlled,	taking	into	account	many	of	
the	methodological	issues	that	can	arise	when	using	the	16S	rRNA	gene	
sequencing	approach	for	the	microbiota10.		
	
There	are	clear	and	reproducible	differences	between	sampling	types	and	areas	
of	the	respiratory	tract.	Choices	have	to	be	made	during	study	design	as	to	the	
method	and	area	most	appropriate	for	the	question	and,	pragmatically,	one	that	
can	be	obtained	at	scale11,12.	In	Toivonen	and	colleagues’	Finnish	cohort,	nasal	
swabs	were	collected.	Nasal	swabs	can	be	expected	to	represent	the	upper	
respiratory	tract	nasal	microbiota	and	infections	that	start	or	are	restricted	to	
the	nasopharynx.	Although,	the	relationship	with	the	lower	respiratory	tract	may	
be	less	well	represented;	the	necessary	sampling	for	this	would	likely	be	
prohibitive	in	a	cohort	of	this	size.			
	
The	authors	stratified	the	infants	according	to	their	nasal	microbiota,	with	each	
of	the	five	resulting	groups	represented	by	a	particular	dominant	organism.	Of	
these	the	highest	reported	incidence	rate	of	respiratory	infections	was	in	the	
Moraxella‐dominant	group	and	lowest	rate	in	the	Corynebacteriaceae	group.		
These	results	echo	that	of	previous,	smaller	longitudinal	studies	of	the	
nasopharyngeal	microbiota	in	infancy	and	add	further	evidence	of	a	potentially	
pathogenic	role	for	Moraxella	and	protective	role	of	Corynebacterium	in	the	risk	
of	developing	ARIs8.		Moraxella	has	also	been	associated	with	respiratory	disease	
in	a	range	of	different	contexts,	such	as	asthma1	and	chronic	obstructive	
pulmonary	disease13.		It	should	be	noted	that	although	rigorous	statistical	
methods	have	been	applied,	there	is	quite	a	large	difference	in	numbers	of	
infants	in	each	of	these	groups	and	a	future	study	might	corroborate	these	
findings	by	the	targeted	recruiting	of	equal	numbers	of	study	participants	in	each	
organism	dominated	group	and	recording	ARI	incidence.	The	lack	of	a	
Haemophilus‐dominated	microbiota	group	is	surprising	as	this	was	identified	in	
a	previous	infant	cohort	as	a	risk	for	ARIs5	and	Haemophilus	is	an	organism	
associated	chronic	lung	diseases	in	childhood	such	as	asthma1	and	primary	
ciliary	dyskinesia14.		This	could	be	a	feature	of	this	cohort	or	might	represent	
methodological	differences	and	is	worthy	of	additional	exploration.		
	
As	Toivonen	et	al	correctly	state	association	does	not	prove	causality.		In	this	
study	a	higher	rate	of	respiratory	viral	detection	was	observed	in	the	Moraxella‐
dominated	group.		Viral	infections	are	recognised	as	a	common	cause	of	ARIs	in	
infancy.		The	authors	of	this	study	were	unfortunately	unable	to	assess	the	
inflammatory	effects	of	different	microbiota	profiles.		Although	viral	infections	
were	adjusted	for	in	their	analyses,	the	interactions	between	viruses,	the	
microbiota	and	host	inflammation	were	not	explored.		In	vitro	work	looking	at	
interactions	within	and	between	microbes	and	the	host	may	help	us	to	better	
understand	the	causal	mechanisms	for	these	differences	and	determine	
therapeutic	targets	for	promotion	of	lung	health.			
	
As	the	authors	continue	to	follow‐up	these	children	longitudinally,	it	will	be	
interesting	to	observe	the	impact	of	different	microbiota	profiles	on	later	
respiratory	health	and	whether	the	children	sampled	stay	within	the	same	
groups.		Recurrent	ARIs	in	the	first	year	of	life	have	been	shown	to	be	a	
significant	risk	factor	for	both	reduced	lung	function	at	one	year	of	age	and	
hospitalisations	with	respiratory	symptoms,	particularly	asthma,	at	three	years	
of	age	in	two	large	population	based	studies	in	children	in	South	Africa15	and	
Australia	respectively16.		Surprisingly,	Toivonen	et	al	did	not	find	an	association	
with	microbiota	profiles	and	recurrent	wheezing,	although	this	may	reflect	the	
low	incidence	of	recurrent	wheezing	in	this	cohort,	and	the	long	term	
implications	of	this	study	on	future	lung	health	remain	unknown.	Nonetheless,	
there	is	a	growing	body	of	evidence	that	interventions	to	reduce	the	severity	and	
frequency	of	ARIs	in	infancy	could	improve	lung	health.			
	
What	such	interventions	should	entail,	however,	is	debatable.		Given	the	
pathogenic	role	of	Moraxella	in	promoting	neutrophilic	airway	inflammation17	
and	disease	susceptibility,	an	argument	could	be	made	for	aggressive	antibiotic	
treatment	for	Moraxella‐dominated	communities.		In	an	era	of	increasing	
antimicrobial	resistance,	caution	should	be	taken	when	advocating	such	an	
approach	in	the	absence	of	evidence	of	causation	between	Moraxella	and	lung	
disease.		The	current	study	reported	greater	use	of	systemic	antibiotics	in	the	
Moraxella	and	Streptococcus‐dominated	groups	before	2	months	of	age.	It	is	
unknown	if	the	need	for	early	antibiotic	treatment	is	a	result	of	or	risk	factor	for	
development	of	a	Moraxella‐dominated	community	as	such	further	longitudinal	
investigation	into	the	development	of	the	microbial	community	in	early	life	is	
required.		
	
The	microbiota	throughout	the	body	has	consistently	been	shown	to	be	highly	
individual18.		Personalised	treatments	based	on	risk‐stratification	by	the	
dominant	organism	in	the	microbiota,	similar	to	that	used	in	this	study,	may	
prove	beneficial.		Such	strategies	have	yet	to	be	evaluated	in	paediatric	cohorts	
in	whom	the	greatest	window	of	opportunity	exists	to	prevent	abberant	
development	of	the	microbiota	and	influence	long‐term	respiratory	health.			
	
The	insights	afforded	by	this	large,	well‐conducted	study	by	Toivonen	et	al	
provide	growing	evidence	that	some	microbiota	profiles,	potentially	those	
dominated	by	Moraxella,	may	be	related	to	an	increased	risk	of	future	lung	
disease.		Future	work	in	this	area	exploring	mechanisms	of	causation	and	
longitudinal	outcomes	will	help	to	determine	if	these	microbiota	profiles	in	
infancy	are	truly	risky	or	innocent	bystanders	in	children	with	increased	risk	of	
ARIs.						
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